Preferred Primary Care Physicians Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$37,942	33
2024	Research	$27,272	14
2023	Research	$51,357	25
2022	Research	$109,991	74
2021	Research	$5,431	20
2020	Research	$11,750	2

Breakdown

Who paid Research payments · program years 2020–2025

Biohaven Pharmaceutical Holding Company Ltd. $132,851 49 payments
H. Lundbeck A S $56,620 45 payments
Pfizer Inc. $46,093 22 payments
Teva Pharmaceuticals USA, Inc. $5,678 51 payments
Currax Pharmaceuticals LLC $2,500 1 payment

Studies the money was for Research payments · program years 2020–2025

A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $84,737 33 payments
A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $65,641 26 payments
A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications $36,784 32 payments
An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents With Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period $19,836 13 payments
A Phase 4 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $18,102 6 payments
A Phase 4 Randomized Doubleblind Placebocontrolled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens $10,465 6 payments
A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice $5,678 51 payments
17-AVP-825-301_Clinical Operations $2,500 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.